Sample report · synthetic data · illustrative example
Pharmacy invoice audit · 48-hour first look

Maple Grove Care Center (fictional)

Period reviewedJul 01, 2026 – Sep 29, 2026
PharmacyNorthbridge Institutional Pharmacy (fictional)
PreparedOctober 15, 2026
Report IDPA-20261015-9802
Identified overbilling
$14,111

Disputable charges found in 91 days of invoices. Each is listed below with its evidence.

Annualized · estimate
$56,600

Period findings × 365 / 91 days. An estimate, not a result.

Compliance exposure
$1,809

Third-party billing during facility-responsible stays. Not savings.

Facility-paid spend reviewed
$74,421

Net of credits. $38.04 per facility-paid resident-day.

Executive summary

$14,111.23 in charges the facility can dispute.

We reviewed 3,433 invoice lines across 3 invoice(s) from Northbridge Institutional Pharmacy (fictional), matched them to 137 residents' census records (8,638 resident-days, average daily census 94.9) and tested them against the pharmacy services agreement.

Identified overbilling is $14,111.23, or 19.0% of net facility-paid charges ($74,420.89). At this run-rate that is an estimated $56,600 a year.

Separately, $1,809.04 of drugs were billed to Part D or another third party while the facility was responsible for the resident's drugs. Correcting this raises facility cost; it reduces regulatory exposure.

$3,178.70 of facility-billed drug charges (3.9% of $81,987.39) fell on days the facility was not in a Part A or facility-responsible managed-care stay. We classified every line: $880.37 should have gone to Part D or Medicaid; $1,784.32 in Part D rejections to review; $45.99 of possible hospice responsibility; $190.28 in retroactive Medicaid credits; $6.00 in OTC pricing above contract. $9.00 appears legitimate under the agreement.

The earliest open dispute deadline under the agreement's 90-day window is October 29, 2026.

Largest drivers
  • Duplicates and missing credits: $5,253.74 across 14 finding(s).
  • Charges after discharge, death or leave of absence: $2,659.24 across 10 finding(s).
  • Facility charges outside Part A: $2,076.59 across 10 finding(s).

Substitution opportunities (estimate, clinical review required): $10,861.06. Not included in the totals above.

Findings by category

Eight checks, in priority order.

CheckTypeFindingsLines Amount
1Payer misbilling (Part A vs. Part D / Medicaid)Overbilling921$902.87
1Third-party billing during a facility-responsible stay (compliance exposure)Exposure46$1,809.04
2Charges after discharge, death or leave of absenceOverbilling1020$2,659.24
3Duplicates and missing creditsOverbilling1459$5,253.74
4Fees against contractOverbilling8320$1,006.25
5Consolidated billing exclusions billed to the facilityOverbilling44$1,916.70
6Price against contractOverbilling218$295.84
7Substitution opportunities (clinical review required)Estimate457$10,861.06
8Facility charges outside Part AOverbilling1043$2,076.59
Identified overbilling (disputable) $14,111.23
Compliance exposure (not savings) $1,809.04
Substitution opportunity (estimate) $10,861.06

No invoice dollar is counted twice: when a line fails more than one check, the higher-priority check keeps it.

Compliance exposure

Part D billed during Part A stays.

$1,809.04

When a resident is in a covered Part A stay, the facility is responsible for their drugs out of the per-diem rate. Drugs billed to Part D (or Medicaid) on those days are improper payments. The OIG has an open Work Plan item on SNFs' financial responsibility for drugs for Part D enrollees in Part A stays, and its audit A-09-21-03008 found up to $465.1M in improper Part D payments of this kind (oig.hhs.gov).

These items do not save money. Correcting them shifts cost to the facility. We list them so the facility can fix the billing before an auditor finds it. This is not legal advice; review with compliance counsel.

IDResidentIssueLinesAmount
C1-001R1098Part D billed during a Medicare Part A stay2$646.80
C1-002R1100Part D billed during a Medicare Part A stay2$606.48
C1-003R1099Part D billed during a Medicare Part A stay1$326.80
C1-004R1101Part D billed during a Medicare Part A stay1$228.96
Charges outside Part A

Where long-stay overpayment hides.

Facility-paid outside Part A: $3,178.70 across 57 drug lines, 3.9% of facility-billed drug charges ($81,987.39). $2,906.96 (91.5%) of it is flagged for review or dispute.

On these days the facility is not responsible for drugs under a Part A stay. Every line was classified in this order: hospice, Medicaid pending, OTC, Part D rejection, contract guarantee, and otherwise "should have gone to Part D / Medicaid" (reported under check 1). "Flagged" counts any check's finding on the line, after de-duplication; linked dispensing fees are in the finding detail, not in this table.

BucketLinesBilledShare FlaggedReported as
Should have gone to Part D / Medicaid12$880.3727.7%$880.37Check 1 findings
Part D rejection passed through to the facility
non-formulary $403.70; other reject reasons $349.27; plan limits / quantity $505.68; prior authorization $296.35; refill too soon $229.32
5$1,784.3256.1%$1,784.32Check 8 findings
Possible hospice responsibility3$45.991.4%$45.99Check 8 findings
Medicaid pending (fronted by the facility)
covered by a retroactive approval $299.18; still pending (watch list) $146.04
28$445.2214.0%$190.28Check 8 findings
OTC / house stock
above contract OTC terms $13.80
3$13.800.4%$6.00Check 8 findings
Legitimate under the agreement
OTC priced within contract terms $9.00
6$9.000.3%$0.00No finding
Total outside Part A57 $3,178.70100%$2,906.96

Part D rejections are flagged as avoidable rejections for review, not as amounts the pharmacy owes. Hospice items need the hospice and the consultant pharmacist to confirm relatedness: we do not receive diagnoses. Charges still in a Medicaid-pending period are listed under credits to watch, not as findings.

Finding detail

Every finding, with its evidence.

Each finding lists the invoice lines, the census record for the service date, the contract clause and a recommended action. Flagged amounts are what the facility can request.

1

Payer misbilling (Part A vs. Part D / Medicaid)

$902.87
F1-001 · R1003

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$570.63Disputable
Evidence

2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1003 in house, payer Medicaid, from 04/14/2026. Last census event: admit on 04/14/2026 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-2108/01/2026R1003Memantine 10 mg TAB9999900100162Facility$86.49$86.49
INV-202608-2208/01/2026R1003Seroquel 50 mg TAB9999900430131Facility$479.14$479.14
INV-202608-2308/01/2026R1003Dispensing Fee999990010011Facility$2.50$2.50
INV-202608-2408/01/2026R1003Dispensing Fee999990043011Facility$2.50$2.50
F1-002 · R1007

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$88.99Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1007 in house, payer Medicaid, from 10/17/2025. Last census event: admit on 10/17/2025 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-4808/01/2026R1007Memantine 10 mg TAB9999900100162Facility$86.49$86.49
INV-202608-5108/01/2026R1007Dispensing Fee999990010011Facility$2.50$2.50
F1-003 · R1008

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$66.98Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1008 in house, payer Medicaid, from 04/01/2025. Last census event: admit on 04/01/2025 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-5408/01/2026R1008Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$64.48
INV-202608-5908/01/2026R1008Dispensing Fee999990006011Facility$2.50$2.50
F1-004 · R1006

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$64.99Disputable
Evidence

2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1006 in house, payer Medicaid, from 04/18/2026. Last census event: admit on 04/18/2026 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-4108/01/2026R1006Donepezil 10 mg TAB9999900090131Facility$39.06$39.06
INV-202608-4408/01/2026R1006Carvedilol 6.25 mg TAB9999900180162Facility$20.93$20.93
INV-202608-4508/01/2026R1006Dispensing Fee999990009011Facility$2.50$2.50
INV-202608-4608/01/2026R1006Dispensing Fee999990018011Facility$2.50$2.50
F1-005 · R1004

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$59.41Disputable
Evidence

2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1004 in house, payer Medicaid, from 07/08/2023. Last census event: admit on 07/08/2023 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-2708/01/2026R1004Quetiapine 25 mg TAB9999900170162Facility$33.48$33.48
INV-202608-2808/01/2026R1004Carvedilol 6.25 mg TAB9999900180162Facility$20.93$20.93
INV-202608-3108/01/2026R1004Dispensing Fee999990017011Facility$2.50$2.50
INV-202608-3208/01/2026R1004Dispensing Fee999990018011Facility$2.50$2.50
F1-006 · R1009

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$17.85Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1009 in house, payer Medicaid, from 08/12/2025. Last census event: admit on 08/12/2025 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-6408/01/2026R1009Mirtazapine 15 mg TAB9999900240131Facility$15.35$15.35
INV-202608-6508/01/2026R1009Dispensing Fee999990024011Facility$2.50$2.50
F1-007 · R1081

Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan

Severity high Confidence high
$11.34Disputable
Evidence

1 drug line(s) dispensed 08/09/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.

Census evidence

Census: R1081 in house, payer Medicaid, from 08/04/2026. Last census event: payer change on 08/04/2026 (payer Medicaid).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-80708/09/2026R1081Cephalexin 500 mg CAP9999900600128Facility$11.34$11.34
F1-008 · R1083

Billed to facility while resident's drugs were the responsibility of Resident / Part D plan

Severity high Confidence medium
$11.34Disputable
Evidence

1 drug line(s) dispensed 08/13/2026 were billed to the facility. On those dates the census payer was Private, and the contract assigns drug cost for Private days to Resident / Part D plan.

Census evidence

Census: R1083 in house, payer Private, from 08/06/2026. Last census event: payer change on 08/06/2026 (payer Private).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Resident / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-88508/13/2026R1083Cephalexin 500 mg CAP9999900600128Facility$11.34$11.34
F1-009 · R1087

Billed to facility while resident's drugs were the responsibility of Resident / Part D plan

Severity high Confidence medium
$11.34Disputable
Evidence

1 drug line(s) dispensed 07/27/2026 were billed to the facility. On those dates the census payer was Private, and the contract assigns drug cost for Private days to Resident / Part D plan.

Census evidence

Census: R1087 in house, payer Private, from 07/20/2026. Last census event: payer change on 07/20/2026 (payer Private).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Request a credit for these lines and ask the pharmacy to rebill Resident / Part D plan. Ask the pharmacy to confirm its payer feed from the census.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-99407/27/2026R1087Cephalexin 500 mg CAP9999900600128Facility$11.34$11.34
1

Third-party billing during a facility-responsible stay (compliance exposure)

$1,809.04
C1-001 · R1098

Part D billed during a Medicare Part A stay

Severity high Confidence high
$646.80Exposure
Evidence

2 drug line(s) dispensed 07/11/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.

Census evidence

Census: R1098 in house, payer MedicareA, 07/11/2026–08/18/2026. Last census event: admit on 07/11/2026 (payer MedicareA).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-80807/11/2026R1098Eliquis 5 mg TAB9999900400142PartD$329.28$329.28
INV-202607-81007/11/2026R1098Januvia 100 mg TAB9999900470121PartD$317.52$317.52
C1-002 · R1100

Part D billed during a Medicare Part A stay

Severity high Confidence high
$606.48Exposure
Evidence

2 drug line(s) dispensed 07/13/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.

Census evidence

Census: R1100 in house, payer MedicareA, 07/13/2026–07/28/2026. Last census event: admit on 07/13/2026 (payer MedicareA).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-85407/13/2026R1100Jardiance 10 mg TAB9999900410119PartD$326.80$326.80
INV-202607-85507/13/2026R1100Seroquel 50 mg TAB9999900430119PartD$279.68$279.68
C1-003 · R1099

Part D billed during a Medicare Part A stay

Severity high Confidence high
$326.80Exposure
Evidence

1 drug line(s) dispensed 07/13/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.

Census evidence

Census: R1099 in house, payer MedicareA, 07/13/2026–08/10/2026. Last census event: admit on 07/13/2026 (payer MedicareA).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-83407/13/2026R1099Jardiance 10 mg TAB9999900410119PartD$326.80$326.80
C1-004 · R1101

Part D billed during a Medicare Part A stay

Severity high Confidence high
$228.96Exposure
Evidence

1 drug line(s) dispensed 07/23/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.

Census evidence

Census: R1101 in house, payer MedicareA, 07/23/2026–08/06/2026. Last census event: admit on 07/23/2026 (payer MedicareA).

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-92407/23/2026R1101Namenda 10 mg TAB9999900440118PartD$228.96$228.96
2

Charges after discharge, death or leave of absence

$2,659.24
F2-001 · R1086

Charges dated while transferred to hospital

Severity medium Confidence high
$376.47Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/06/2026, while transferred to hospital. The resident was not in the building on these service dates.

Census evidence

Census: R1086 in hospital (transferred out) 07/06/2026–07/09/2026 (last payer MedicareA). Last census event: hospital transfer on 07/05/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-70807/06/2026R1086Namenda 10 mg TAB9999900440128Facility$373.97$373.97
INV-202607-70907/06/2026R1086Dispensing Fee999990044011Facility$2.50$2.50
F2-002 · R1086

Charges dated after discharge

Severity high Confidence high
$376.47Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/31/2026, after discharge. The resident was not in the building on these service dates.

Census evidence

Census: R1086 discharged from 07/28/2026 (last payer MedicareA). Last census event: discharge on 07/27/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-103207/31/2026R1086Namenda 10 mg TAB9999900440128Facility$373.97$373.97
INV-202607-103307/31/2026R1086Dispensing Fee999990044011Facility$2.50$2.50
F2-003 · R1102

Charges dated after death

Severity high Confidence high
$376.47Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 08/30/2026, after death. The resident was not in the building on these service dates.

Census evidence

Census: R1102 deceased from 08/28/2026 (last payer MedicareA). Last census event: death on 08/27/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-118508/30/2026R1102Namenda 10 mg TAB9999900440128Facility$373.97$373.97
INV-202608-118608/30/2026R1102Dispensing Fee999990044011Facility$2.50$2.50
F2-004 · R1088

Charges dated after discharge

Severity high Confidence high
$265.92Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/12/2026, after discharge. The resident was not in the building on these service dates.

Census evidence

Census: R1088 discharged from 07/10/2026 (last payer MedicareA). Last census event: discharge on 07/09/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-82107/12/2026R1088Entresto 49-51 mg TAB9999900480128Facility$263.42$263.42
INV-202607-82207/12/2026R1088Dispensing Fee999990048011Facility$2.50$2.50
F2-005 · R1089

Charges dated while transferred to hospital

Severity medium Confidence high
$265.92Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/22/2026, while transferred to hospital. The resident was not in the building on these service dates.

Census evidence

Census: R1089 in hospital (transferred out) 07/22/2026–07/24/2026 (last payer MedicareA). Last census event: hospital transfer on 07/21/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-90407/22/2026R1089Entresto 49-51 mg TAB9999900480128Facility$263.42$263.42
INV-202607-90507/22/2026R1089Dispensing Fee999990048011Facility$2.50$2.50
F2-006 · R1085

Charges dated after discharge

Severity high Confidence high
$255.34Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/10/2026, after discharge. The resident was not in the building on these service dates.

Census evidence

Census: R1085 discharged from 07/06/2026 (last payer MedicareA). Last census event: discharge on 07/05/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-77807/10/2026R1085Jardiance 10 mg TAB9999900410114Facility$252.84$252.84
INV-202607-77907/10/2026R1085Dispensing Fee999990041011Facility$2.50$2.50
F2-007 · R1099

Charges dated after death

Severity high Confidence high
$255.34Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 08/13/2026, after death. The resident was not in the building on these service dates.

Census evidence

Census: R1099 deceased from 08/11/2026 (last payer MedicareA). Last census event: death on 08/10/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-88608/13/2026R1099Jardiance 10 mg TAB9999900410114Facility$252.84$252.84
INV-202608-88708/13/2026R1099Dispensing Fee999990041011Facility$2.50$2.50
F2-008 · R1084

Charges dated after discharge

Severity high Confidence high
$233.00Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 07/04/2026, after discharge. The resident was not in the building on these service dates.

Census evidence

Census: R1084 discharged from 07/02/2026 (last payer MedicareA). Last census event: discharge on 07/01/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-70307/04/2026R1084Eliquis 5 mg TAB9999900400128Facility$230.50$230.50
INV-202607-70407/04/2026R1084Dispensing Fee999990040011Facility$2.50$2.50
F2-009 · R1103

Charges dated during leave of absence

Severity medium Confidence medium
$211.83Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 08/01/2026, during leave of absence. The resident was not in the building on these service dates.

Census evidence

Census: R1103 on leave of absence 08/01/2026–08/01/2026 (last payer MedicareA). Last census event: loa start on 07/31/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-66208/01/2026R1103Linzess 145 mcg CAP9999900490114Facility$209.33$209.33
INV-202608-66308/01/2026R1103Dispensing Fee999990049011Facility$2.50$2.50
F2-010 · R1112

Charges dated during leave of absence

Severity medium Confidence medium
$42.48Disputable
Evidence

2 facility-billed line(s) (1 fee line(s)) dated 08/14/2026, during leave of absence. The resident was not in the building on these service dates.

Census evidence

Census: R1112 on leave of absence 08/14/2026–08/14/2026 (last payer MedicareA). Last census event: loa start on 08/13/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-90608/14/2026R1112Synthroid 75 mcg TAB9999900450114Facility$39.98$39.98
INV-202608-90708/14/2026R1112Dispensing Fee999990045011Facility$2.50$2.50
3

Duplicates and missing credits

$5,253.74
F3-001 · R1092

No credit for unused medication after discharge

Severity medium Confidence medium
$1,130.93Disputable
Evidence

Resident discharge on 07/06/2026. 7 facility-paid fill(s) had unused, returnable supply (25, 25, 25, 25, 25, 25, 25 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.

Census evidence

Census: R1092 discharged from 07/07/2026 (last payer MedicareA). Last census event: discharge on 07/06/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-64107/01/2026R1092Senna 8.6 mg TAB9999900130162Facility$2.79$2.25
INV-202607-64207/01/2026R1092Acetaminophen 500 mg TAB9999900150193Facility$2.51$2.02
INV-202607-64307/01/2026R1092Tamsulosin 0.4 mg CAP9999900160131Facility$22.32$18.00
INV-202607-64507/01/2026R1092Escitalopram 10 mg TAB9999900230131Facility$20.93$16.88
INV-202607-64607/01/2026R1092Mirtazapine 15 mg TAB9999900240131Facility$15.35$12.38
INV-202607-64707/01/2026R1092Eliquis 5 mg TAB9999900400162Facility$510.38$411.60
INV-202607-64807/01/2026R1092Namenda 10 mg TAB9999900440162Facility$828.07$667.80
F3-002 · R1085

No credit for unused medication after discharge

Severity medium Confidence medium
$913.43Disputable
Evidence

Resident discharge on 07/05/2026. 8 facility-paid fill(s) had unused, returnable supply (26, 26, 26, 26, 26, 26, 26, 26 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.

Census evidence

Census: R1085 discharged from 07/06/2026 (last payer MedicareA). Last census event: discharge on 07/05/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-54507/01/2026R1085Donepezil 10 mg TAB9999900090131Facility$39.06$32.76
INV-202607-54607/01/2026R1085Memantine 10 mg TAB9999900100162Facility$86.49$72.54
INV-202607-54707/01/2026R1085Metformin 500 mg TAB9999900110162Facility$9.77$8.19
INV-202607-54807/01/2026R1085Acetaminophen 500 mg TAB9999900150193Facility$2.51$2.11
INV-202607-54907/01/2026R1085Vitamin D3 1000 unit TAB9999900190131Facility$0.70$0.59
INV-202607-55207/01/2026R1085Escitalopram 10 mg TAB9999900230131Facility$20.93$17.55
INV-202607-55307/01/2026R1085Jardiance 10 mg TAB9999900410131Facility$559.86$469.56
INV-202607-55407/01/2026R1085Lipitor 40 mg TAB9999900420131Facility$369.77$310.13
F3-003 · R1089

No credit for unused medication after discharge

Severity medium Confidence medium
$907.24Disputable
Evidence

Resident discharge on 08/13/2026. 7 facility-paid fill(s) had unused, returnable supply (18, 18, 18, 18, 18, 18, 18 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.

Census evidence

Census: R1089 discharged from 08/14/2026 (last payer MedicareA). Last census event: discharge on 08/13/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-50808/01/2026R1089Amlodipine 5 mg TAB9999900010131Facility$11.86$6.89
INV-202608-50908/01/2026R1089Furosemide 40 mg TAB9999900050131Facility$5.58$3.24
INV-202608-51008/01/2026R1089Levothyroxine 50 mcg TAB9999900070131Facility$12.56$7.29
INV-202608-51108/01/2026R1089Sertraline 50 mg TAB9999900080131Facility$19.53$11.34
INV-202608-51408/01/2026R1089Jardiance 10 mg TAB9999900410131Facility$559.86$325.08
INV-202608-51508/01/2026R1089Lipitor 40 mg TAB9999900420131Facility$369.77$214.71
INV-202608-51608/01/2026R1089Entresto 49-51 mg TAB9999900480162Facility$583.30$338.69
F3-004 · R1104

No credit for unused medication after discharge

Severity medium Confidence medium
$803.96Disputable
Evidence

Resident discharge on 08/16/2026. 10 facility-paid fill(s) had unused, returnable supply (15, 15, 15, 15, 15, 15, 15, 15, 15, 15 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.

Census evidence

Census: R1104 discharged from 08/17/2026 (last payer MedicareA). Last census event: discharge on 08/16/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-101207/30/2026R1104Amlodipine 5 mg TAB9999900010133Facility$12.62$5.74
INV-202607-101307/30/2026R1104Pantoprazole 40 mg TAB EC9999900060133Facility$47.52$21.60
INV-202607-101407/30/2026R1104Memantine 10 mg TAB9999900100166Facility$92.07$41.85
INV-202607-101507/30/2026R1104Gabapentin 300 mg CAP9999900120199Facility$31.19$14.18
INV-202607-101607/30/2026R1104Acetaminophen 500 mg TAB9999900150199Facility$2.67$1.21
INV-202607-101707/30/2026R1104Quetiapine 25 mg TAB9999900170166Facility$35.64$16.20
INV-202607-101807/30/2026R1104Carvedilol 6.25 mg TAB9999900180166Facility$22.28$10.13
INV-202607-101907/30/2026R1104Escitalopram 10 mg TAB9999900230133Facility$22.28$10.13
INV-202607-102007/30/2026R1104Namenda 10 mg TAB9999900440166Facility$881.50$400.68
INV-202607-102107/30/2026R1104Entresto 49-51 mg TAB9999900480166Facility$620.93$282.24
F3-005 · R1099

No credit for unused medication after death

Severity medium Confidence medium
$753.83Disputable
Evidence

Resident death on 08/10/2026. 9 facility-paid fill(s) had unused, returnable supply (21, 21, 21, 21, 21, 21, 21, 21, 21 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.

Census evidence

Census: R1099 deceased from 08/11/2026 (last payer MedicareA). Last census event: death on 08/10/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-60208/01/2026R1099Amlodipine 5 mg TAB9999900010131Facility$11.86$8.03
INV-202608-60308/01/2026R1099Furosemide 40 mg TAB9999900050131Facility$5.58$3.78
INV-202608-60408/01/2026R1099Donepezil 10 mg TAB9999900090131Facility$39.06$26.46
INV-202608-60508/01/2026R1099Metformin 500 mg TAB9999900110162Facility$9.77$6.62
INV-202608-60608/01/2026R1099Senna 8.6 mg TAB9999900130162Facility$2.79$1.89
INV-202608-60708/01/2026R1099Docusate 100 mg CAP9999900140162Facility$2.23$1.51
INV-202608-60808/01/2026R1099Acetaminophen 500 mg TAB9999900150193Facility$2.51$1.70
INV-202608-61008/01/2026R1099Jardiance 10 mg TAB9999900410131Facility$559.86$379.26
INV-202608-61108/01/2026R1099Seroquel 50 mg TAB9999900430131Facility$479.14$324.58
F3-006 · R1088

No credit for unused medication after discharge

Severity medium Confidence medium
$602.58Disputable
Evidence

Resident discharge on 07/09/2026. 11 facility-paid fill(s) had unused, returnable supply (22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show a partial credit. Controlled substances are excluded.

Census evidence

Census: R1088 discharged from 07/10/2026 (last payer MedicareA). Last census event: discharge on 07/09/2026.

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-59907/01/2026R1088Furosemide 40 mg TAB9999900050131Facility$5.58$1.98
INV-202607-60007/01/2026R1088Pantoprazole 40 mg TAB EC9999900060131Facility$44.64$15.84
INV-202607-60107/01/2026R1088Metformin 500 mg TAB9999900110162Facility$9.77$3.46
INV-202607-60207/01/2026R1088Gabapentin 300 mg CAP9999900120193Facility$29.30$10.39
INV-202607-60307/01/2026R1088Acetaminophen 500 mg TAB9999900150193Facility$2.51$0.89
INV-202607-60407/01/2026R1088Carvedilol 6.25 mg TAB9999900180162Facility$20.93$7.42
INV-202607-60707/01/2026R1088Mirtazapine 15 mg TAB9999900240131Facility$15.35$5.44
INV-202607-60807/01/2026R1088Seroquel 50 mg TAB9999900430131Facility$479.14$170.01
INV-202607-60907/01/2026R1088Xarelto 20 mg TAB9999900460131Facility$507.78$180.18
INV-202607-61007/01/2026R1088Entresto 49-51 mg TAB9999900480162Facility$583.30$206.97
F3-007 · R1063

Refilled early with no credit: Memantine 10 mg TAB

Severity medium Confidence low
$55.80Disputable
Evidence

Memantine 10 mg TAB was dispensed 08/01/2026 for 31 days (through 08/31/2026) and dispensed again 08/12/2026. 20 days of supply overlap and no credit for the first fill appears. Flagged amount is the overlapping share of the second fill.

Census evidence

Census: R1063 in house, payer ManagedCare, from 11/13/2024. Last census event: admit on 11/13/2024 (payer ManagedCare).

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Check the order history for a dose change. If none, request credit for the overlapping supply or return of the first fill.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-86608/12/2026R1063Memantine 10 mg TAB9999900100140Facility$55.80$55.80
INV-202608-33208/01/2026R1063Memantine 10 mg TAB9999900100162Facility$86.49$0.00
F3-008 · R1086

Duplicate charge: Gabapentin 300 mg CAP

Severity high Confidence high
$29.30Disputable
Evidence

Gabapentin 300 mg CAP (NDC 99999001201), qty 93, $29.30 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-569) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1086 in house, payer MedicareA, 06/11/2026–07/05/2026. Last census event: admit on 06/11/2026 (payer MedicareA).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-207/01/2026R1086Gabapentin 300 mg CAP9999900120193Facility$29.30$29.30
INV-202607-56907/01/2026R1086Gabapentin 300 mg CAP9999900120193Facility$29.30$0.00
F3-009 · R1123

Duplicate charge: Escitalopram 10 mg TAB

Severity high Confidence high
$19.58Disputable
Evidence

Escitalopram 10 mg TAB (NDC 99999002301), qty 29, $19.58 dispensed 09/02/2026 was billed 2 times (invoices INV-202609). The first charge (line INV-202609-814) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1123 in house, payer MedicareA, 09/02/2026–09/30/2026. Last census event: admit on 09/02/2026 (payer MedicareA).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-81509/02/2026R1123Escitalopram 10 mg TAB9999900230129Facility$19.58$19.58
INV-202609-81409/02/2026R1123Escitalopram 10 mg TAB9999900230129Facility$19.58$0.00
F3-010 · R1064

Duplicate charge: Mirtazapine 15 mg TAB

Severity high Confidence high
$15.35Disputable
Evidence

Mirtazapine 15 mg TAB (NDC 99999002401), qty 31, $15.35 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-372) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1064 in house, payer ManagedCare, from 04/17/2025. Last census event: admit on 04/17/2025 (payer ManagedCare).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-107/01/2026R1064Mirtazapine 15 mg TAB9999900240131Facility$15.35$15.35
INV-202607-37207/01/2026R1064Mirtazapine 15 mg TAB9999900240131Facility$15.35$0.00
F3-011 · R1100

Duplicate charge: Escitalopram 10 mg TAB

Severity high Confidence high
$12.83Disputable
Evidence

Escitalopram 10 mg TAB (NDC 99999002301), qty 19, $12.83 dispensed 07/13/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-852) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1100 in house, payer MedicareA, 07/13/2026–07/28/2026. Last census event: admit on 07/13/2026 (payer MedicareA).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-507/13/2026R1100Escitalopram 10 mg TAB9999900230119Facility$12.83$12.83
INV-202607-85207/13/2026R1100Escitalopram 10 mg TAB9999900230119Facility$12.83$0.00
F3-012 · R1088

Duplicate charge: Furosemide 40 mg TAB

Severity high Confidence high
$5.58Disputable
Evidence

Furosemide 40 mg TAB (NDC 99999000501), qty 31, $5.58 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-599) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1088 in house, payer MedicareA, 06/26/2026–07/09/2026. Last census event: admit on 06/26/2026 (payer MedicareA).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-307/01/2026R1088Furosemide 40 mg TAB9999900050131Facility$5.58$5.58
INV-202607-59907/01/2026R1088Furosemide 40 mg TAB9999900050131Facility$5.58$0.00
F3-013 · R1099

Duplicate charge: Senna 8.6 mg TAB

Severity high Confidence high
$1.71Disputable
Evidence

Senna 8.6 mg TAB (NDC 99999001301), qty 38, $1.71 dispensed 07/13/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-830) is treated as valid; 1 repeat charge(s) are flagged.

Census evidence

Census: R1099 in house, payer MedicareA, 07/13/2026–08/10/2026. Last census event: admit on 07/13/2026 (payer MedicareA).

Contract clause

§9.2 (Invoice Disputes): disputes within 90 days of invoice date

Recommended action

Request credit for each repeat charge.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-407/13/2026R1099Senna 8.6 mg TAB9999900130138Facility$1.71$1.71
INV-202607-83007/13/2026R1099Senna 8.6 mg TAB9999900130138Facility$1.71$0.00
F3-014 · R1028

Refilled early with no credit: Acetaminophen 500 mg TAB

Severity medium Confidence low
$1.62Disputable
Evidence

Acetaminophen 500 mg TAB was dispensed 08/01/2026 for 31 days (through 08/31/2026) and dispensed again 08/12/2026. 20 days of supply overlap and no credit for the first fill appears. Flagged amount is the overlapping share of the second fill.

Census evidence

Census: R1028 in house, payer ManagedCare, from 09/20/2024. Last census event: admit on 09/20/2024 (payer ManagedCare).

Contract clause

§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation

Recommended action

Check the order history for a dose change. If none, request credit for the overlapping supply or return of the first fill.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-86508/12/2026R1028Acetaminophen 500 mg TAB9999900150160Facility$1.62$1.62
INV-202608-15708/01/2026R1028Acetaminophen 500 mg TAB9999900150193Facility$2.51$0.00
4

Fees against contract

$1,006.25
F4-001

Dispensing fee: charged above the contract rate (2026-09)

Severity medium Confidence high
$376.25Disputable
Evidence

301 dispensing fee line(s), 301 unit(s), in 2026-09. Charged $3.75 per unit against a contract rate of $2.50 per rx.

Contract clause

Exhibit B §2.1 (Dispensing Fee)

Recommended action

Request credit for the amount above contract.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-14309/01/2026R1028Dispensing Fee999990015011Facility$3.75$1.25
INV-202609-14409/01/2026R1028Dispensing Fee999990016011Facility$3.75$1.25
INV-202609-14509/01/2026R1028Dispensing Fee999990018011Facility$3.75$1.25
INV-202609-14609/01/2026R1028Dispensing Fee999990020011Facility$3.75$1.25
INV-202609-19309/01/2026R1038Dispensing Fee999990001011Facility$3.75$1.25
INV-202609-19409/01/2026R1038Dispensing Fee999990002011Facility$3.75$1.25
INV-202609-19509/01/2026R1038Dispensing Fee999990003011Facility$3.75$1.25
INV-202609-19609/01/2026R1038Dispensing Fee999990006011Facility$3.75$1.25
INV-202609-19709/01/2026R1038Dispensing Fee999990011011Facility$3.75$1.25
INV-202609-19809/01/2026R1038Dispensing Fee999990016011Facility$3.75$1.25
INV-202609-19909/01/2026R1038Dispensing Fee999990023011Facility$3.75$1.25
INV-202609-23109/01/2026R1045Dispensing Fee999990003011Facility$3.75$1.25
INV-202609-23209/01/2026R1045Dispensing Fee999990008011Facility$3.75$1.25
INV-202609-23309/01/2026R1045Dispensing Fee999990011011Facility$3.75$1.25
INV-202609-23409/01/2026R1045Dispensing Fee999990023011Facility$3.75$1.25
INV-202609-23509/01/2026R1045Dispensing Fee999990042011Facility$3.75$1.25
INV-202609-28409/01/2026R1055Dispensing Fee999990014011Facility$3.75$1.25
INV-202609-28509/01/2026R1055Dispensing Fee999990015011Facility$3.75$1.25
INV-202609-28609/01/2026R1055Dispensing Fee999990019011Facility$3.75$1.25
INV-202609-28709/01/2026R1055Dispensing Fee999990022011Facility$3.75$1.25
INV-202609-28809/01/2026R1055Dispensing Fee999990048011Facility$3.75$1.25
INV-202609-33309/01/2026R1063Dispensing Fee999990010011Facility$3.75$1.25
INV-202609-33409/01/2026R1063Dispensing Fee999990012011Facility$3.75$1.25
INV-202609-33509/01/2026R1063Dispensing Fee999990017011Facility$3.75$1.25
INV-202609-33609/01/2026R1063Dispensing Fee999990023011Facility$3.75$1.25

276 more line(s) in finding_lines.csv.

F4-002

Ekit fee: charged more often than the contract allows (2026-08)

Severity medium Confidence high
$150.00Disputable
Evidence

1 ekit fee line(s), 1 unit(s), in 2026-08. The contract allows 1 per month.

Contract clause

Exhibit B §2.4 (Emergency Kit)

Recommended action

Request credit for the amount above contract.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-90808/15/2026E-Kit Monthly Fee1Facility$150.00$150.00
F4-003 · R1095

Iv admin fee: charged above the contract rate (2026-07)

Severity medium Confidence high
$140.00Disputable
Evidence

7 iv admin fee line(s), 7 unit(s), in 2026-07. Charged $95.00 per unit against a contract rate of $75.00 per day.

Contract clause

Exhibit C §1 (Infusion Services)

Recommended action

Request credit for the amount above contract.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-70207/03/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-70507/04/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-70607/05/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-71007/06/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-73607/07/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-73807/08/2026R1095IV Administration Per Diem1Facility$95.00$20.00
INV-202607-77507/09/2026R1095IV Administration Per Diem1Facility$95.00$20.00
F4-004

Stat delivery fee: charged more often than the contract allows (2026-08)

Severity medium Confidence high
$105.00Disputable
Evidence

3 stat delivery fee line(s), 3 unit(s), in 2026-08. The contract allows 4 per month.

Contract clause

Exhibit B §2.3 (STAT Delivery)

Recommended action

Request credit for the amount above contract.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-104508/21/2026STAT Delivery1Facility$35.00$35.00
INV-202608-104608/22/2026STAT Delivery1Facility$35.00$35.00
INV-202608-110308/23/2026STAT Delivery1Facility$35.00$35.00
F4-005

Delivery fee: charged above the contract rate (2026-07)

Severity medium Confidence high
$100.00Disputable
Evidence

5 delivery fee line(s), 5 unit(s), in 2026-07. Charged $20.00 per unit against a contract rate of $0.00 per delivery.

Contract clause

Exhibit B §2.2 (Delivery) (routine deliveries included)

Recommended action

Request credit for the amount above contract.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-70007/03/2026Routine Delivery1Facility$20.00$20.00
INV-202607-73707/08/2026Routine Delivery1Facility$20.00$20.00
INV-202607-82407/13/2026Routine Delivery1Facility$20.00$20.00
INV-202607-90107/18/2026Routine Delivery1Facility$20.00$20.00
INV-202607-90607/23/2026Routine Delivery1Facility$20.00$20.00
F4-006

Pkg fee: fee type not listed in the pharmacy services agreement (2026-07)

Severity high Confidence high
$45.00Disputable
Evidence

1 pkg fee line(s), 1 unit(s), in 2026-07. The agreement lists no such fee and does not permit unlisted fees.

Contract clause

Exhibit B §2 (Fees): no fees other than those listed

Recommended action

Request credit for the amount above contract.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-87707/15/2026Packaging Fee1Facility$45.00$45.00
F4-007

Pkg fee: fee type not listed in the pharmacy services agreement (2026-08)

Severity high Confidence high
$45.00Disputable
Evidence

1 pkg fee line(s), 1 unit(s), in 2026-08. The agreement lists no such fee and does not permit unlisted fees.

Contract clause

Exhibit B §2 (Fees): no fees other than those listed

Recommended action

Request credit for the amount above contract.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-90908/15/2026Packaging Fee1Facility$45.00$45.00
F4-008

Pkg fee: fee type not listed in the pharmacy services agreement (2026-09)

Severity high Confidence high
$45.00Disputable
Evidence

1 pkg fee line(s), 1 unit(s), in 2026-09. The agreement lists no such fee and does not permit unlisted fees.

Contract clause

Exhibit B §2 (Fees): no fees other than those listed

Recommended action

Request credit for the amount above contract.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-97909/15/2026Packaging Fee1Facility$45.00$45.00
5

Consolidated billing exclusions billed to the facility

$1,916.70
F5-001 · R1102

CB-excluded drug billed to facility during Part A: Leuprolide Acetate 22.5 mg DEPOT KIT

Severity high Confidence high
$1,596.00Disputable
Evidence

Leuprolide Acetate 22.5 mg DEPOT KIT (Chemotherapy; HCPCS J9217 / J9218) dispensed 07/27/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Chemotherapy HCPCS code on the CB exclusion list. Confirm the billed code and indication. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.

Census evidence

Census: R1102 in house, payer MedicareA, 07/24/2026–08/27/2026. Last census event: admit on 07/24/2026 (payer MedicareA).

Contract clause

§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing

Recommended action

Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-99507/27/2026R1102Leuprolide Acetate 22.5 mg DEPOT KIT999990063011Facility$1,596.00$1,596.00
F5-002 · R1097

CB-excluded drug billed to facility during Part A: Epoetin Alfa 10,000 unit/mL VIAL

Severity high Confidence medium
$117.60Disputable
Evidence

Epoetin Alfa 10,000 unit/mL VIAL (ESRD-related drug (EPO); HCPCS J0885 / Q4081 / Q5106) dispensed 07/10/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Applies to ESRD-related use (resident receiving dialysis). Confirm diagnosis. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.

Census evidence

Census: R1097 in house, payer MedicareA, 07/08/2026–08/16/2026. Last census event: admit on 07/08/2026 (payer MedicareA).

Contract clause

§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing

Recommended action

Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-79707/10/2026R1097Epoetin Alfa 10,000 unit/mL VIAL999990062011Facility$117.60$117.60
F5-003 · R1097

CB-excluded drug billed to facility during Part A: Epoetin Alfa 10,000 unit/mL VIAL

Severity high Confidence medium
$117.60Disputable
Evidence

Epoetin Alfa 10,000 unit/mL VIAL (ESRD-related drug (EPO); HCPCS J0885 / Q4081 / Q5106) dispensed 07/14/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Applies to ESRD-related use (resident receiving dialysis). Confirm diagnosis. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.

Census evidence

Census: R1097 in house, payer MedicareA, 07/08/2026–08/16/2026. Last census event: admit on 07/08/2026 (payer MedicareA).

Contract clause

§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing

Recommended action

Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-87607/14/2026R1097Epoetin Alfa 10,000 unit/mL VIAL999990062011Facility$117.60$117.60
F5-004 · R1104

CB-excluded drug billed to facility during Part A: Doxorubicin 50 mg VIAL

Severity high Confidence high
$85.50Disputable
Evidence

Doxorubicin 50 mg VIAL (Chemotherapy; HCPCS J9000–J9999 range (verify)) dispensed 08/03/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Chemotherapy HCPCS code on the CB exclusion list. Confirm the billed code. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.

Census evidence

Census: R1104 in house, payer MedicareA, 07/30/2026–08/16/2026. Last census event: admit on 07/30/2026 (payer MedicareA).

Contract clause

§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing

Recommended action

Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-74808/03/2026R1104Doxorubicin 50 mg VIAL999990064012Facility$85.50$85.50
6

Price against contract

$295.84
F6-001

Priced above contract: Pantoprazole 40 mg TAB EC

Severity medium Confidence high
$225.28Disputable
Evidence

17 line(s) of Pantoprazole 40 mg TAB EC (NDC 99999000601) billed at $2.08 per unit. Contract price: AWP $3.2000 less 55% (generic) = $1.4400 per unit. AWP is as printed on the pharmacy invoice.

Contract clause

Exhibit B §1 (Drug Pricing): brand AWP less 16%; generic AWP less 55%

Recommended action

Request credit for the difference and ask the pharmacy to correct its price file.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-45308/01/2026R1081Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$19.84
INV-202608-57908/01/2026R1098Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$19.84
INV-202608-62208/01/2026R1101Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$19.84
INV-202608-64208/01/2026R1102Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$19.84
INV-202608-66508/01/2026R1106Pantoprazole 40 mg TAB EC9999900060131Facility$64.48$19.84
INV-202608-76908/04/2026R1109Pantoprazole 40 mg TAB EC9999900060128Facility$58.24$17.92
INV-202608-79108/06/2026R1110Pantoprazole 40 mg TAB EC9999900060126Facility$54.08$16.64
INV-202608-82508/09/2026R1112Pantoprazole 40 mg TAB EC9999900060123Facility$47.84$14.72
INV-202608-84708/10/2026R1058Pantoprazole 40 mg TAB EC9999900060122Facility$45.76$14.08
INV-202608-92708/15/2026R1116Pantoprazole 40 mg TAB EC9999900060117Facility$35.36$10.88
INV-202608-105008/22/2026R1038Pantoprazole 40 mg TAB EC9999900060110Facility$20.80$6.40
INV-202608-106208/22/2026R1098Pantoprazole 40 mg TAB EC9999900060110Facility$20.80$6.40
INV-202608-108708/22/2026R1120Pantoprazole 40 mg TAB EC9999900060110Facility$20.80$6.40
INV-202608-111708/24/2026R1077Pantoprazole 40 mg TAB EC999990006018Facility$16.64$5.12
INV-202608-113008/24/2026R1121Pantoprazole 40 mg TAB EC999990006018Facility$16.64$5.12
INV-202608-117108/27/2026R1050Pantoprazole 40 mg TAB EC9999900060135Facility$72.80$22.40
F6-002

Priced above contract: Eliquis 5 mg TAB

Severity medium Confidence high
$70.56Disputable
Evidence

2 line(s) of Eliquis 5 mg TAB (NDC 99999004001) billed at $8.82 per unit. Contract price: AWP $9.8000 less 16% (brand) = $8.2320 per unit. AWP is as printed on the pharmacy invoice.

Contract clause

Exhibit B §1 (Drug Pricing): brand AWP less 16%; generic AWP less 55%

Recommended action

Request credit for the difference and ask the pharmacy to correct its price file.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-51609/01/2026R1098Eliquis 5 mg TAB9999900400160Facility$529.20$35.28
INV-202609-70709/01/2026R1118Eliquis 5 mg TAB9999900400160Facility$529.20$35.28
7

Substitution opportunities (clinical review required)

$10,861.06

Opportunities, not overbilling. Dollar figures are estimates based on an assumed 50% lower cost for the generic. Every item requires clinical pharmacist and prescriber review before any change.

S7-001

Namenda → generic memantine (estimate; clinical review required)

Severity low Confidence low
$6,117.08Estimate
Evidence

25 facility-paid line(s) of brand Namenda, $15,065.57 total, across 14 resident(s). A generic (memantine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.

Contract clause

Formulary / therapeutic interchange terms (if any)

Recommended action

Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-57207/01/2026R1086Namenda 10 mg TAB9999900440162Facility$828.07$414.04
INV-202607-78707/10/2026R1086Namenda 10 mg TAB9999900440144Facility$587.66$293.83
INV-202607-94307/24/2026R1102Namenda 10 mg TAB9999900440116Facility$213.70$106.85
INV-202608-63108/01/2026R1101Namenda 10 mg TAB9999900440162Facility$828.07$414.04
INV-202608-65108/01/2026R1102Namenda 10 mg TAB9999900440162Facility$828.07$414.04
INV-202608-77508/04/2026R1109Namenda 10 mg TAB9999900440156Facility$747.94$373.97
INV-202608-87408/12/2026R1113Namenda 10 mg TAB9999900440140Facility$534.24$267.12
INV-202608-89608/13/2026R1114Namenda 10 mg TAB9999900440138Facility$507.53$253.77
INV-202608-95608/16/2026R1117Namenda 10 mg TAB9999900440132Facility$427.39$213.70
INV-202608-97608/16/2026R1118Namenda 10 mg TAB9999900440132Facility$427.39$213.70
INV-202608-100408/17/2026R1119Namenda 10 mg TAB9999900440130Facility$400.68$200.34
INV-202608-109208/22/2026R1120Namenda 10 mg TAB9999900440120Facility$267.12$133.56
INV-202609-59209/01/2026R1109Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-64809/01/2026R1114Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-68909/01/2026R1117Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-70909/01/2026R1118Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-72909/01/2026R1119Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-74909/01/2026R1120Namenda 10 mg TAB9999900440160Facility$801.36$400.68
INV-202609-94609/12/2026R1129Namenda 10 mg TAB9999900440138Facility$507.53$253.77
INV-202609-105609/19/2026R1132Namenda 10 mg TAB9999900440124Facility$320.54$160.27
S7-002

Lipitor → generic atorvastatin (estimate; clinical review required)

Severity low Confidence low
$2,481.07Estimate
Evidence

20 facility-paid line(s) of brand Lipitor, $5,701.59 total, across 10 resident(s). A generic (atorvastatin) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.

Contract clause

Formulary / therapeutic interchange terms (if any)

Recommended action

Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-40107/01/2026R1068Lipitor 40 mg TAB9999900420131Facility$369.77$184.89
INV-202607-63007/01/2026R1089Lipitor 40 mg TAB9999900420131Facility$369.77$184.89
INV-202607-80907/11/2026R1098Lipitor 40 mg TAB9999900420121Facility$250.49$125.25
INV-202607-96107/25/2026R1089Lipitor 40 mg TAB999990042017Facility$83.50$41.75
INV-202608-37508/01/2026R1068Lipitor 40 mg TAB9999900420131Facility$369.77$184.89
INV-202608-58808/01/2026R1098Lipitor 40 mg TAB9999900420131Facility$369.77$184.89
INV-202608-69308/01/2026R1107Lipitor 40 mg TAB9999900420131Facility$369.77$184.89
INV-202608-107108/22/2026R1098Lipitor 40 mg TAB9999900420110Facility$119.28$59.64
INV-202608-110808/23/2026R1045Lipitor 40 mg TAB999990042019Facility$107.35$53.68
INV-202608-113608/24/2026R1121Lipitor 40 mg TAB999990042018Facility$95.42$47.71
INV-202608-115708/24/2026R1122Lipitor 40 mg TAB999990042018Facility$95.42$47.71
INV-202609-23009/01/2026R1045Lipitor 40 mg TAB9999900420130Facility$357.84$178.92
INV-202609-36509/01/2026R1068Lipitor 40 mg TAB9999900420130Facility$357.84$178.92
INV-202609-51709/01/2026R1098Lipitor 40 mg TAB9999900420130Facility$357.84$178.92
INV-202609-55709/01/2026R1107Lipitor 40 mg TAB9999900420130Facility$357.84$178.92
INV-202609-76909/01/2026R1122Lipitor 40 mg TAB9999900420130Facility$357.84$178.92
INV-202609-81609/02/2026R1123Lipitor 40 mg TAB9999900420129Facility$345.91$172.96
INV-202609-94509/12/2026R1129Lipitor 40 mg TAB9999900420119Facility$226.63$113.32
S7-003

Seroquel → generic quetiapine (estimate; clinical review required)

Severity low Confidence low
$2,001.56Estimate
Evidence

14 facility-paid line(s) of brand Seroquel, $5,440.53 total, across 9 resident(s). A generic (quetiapine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.

Contract clause

Formulary / therapeutic interchange terms (if any)

Recommended action

Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-36207/01/2026R1063Seroquel 50 mg TAB9999900430131Facility$479.14$239.57
INV-202607-83507/13/2026R1099Seroquel 50 mg TAB9999900430119Facility$293.66$146.83
INV-202608-33608/01/2026R1063Seroquel 50 mg TAB9999900430131Facility$479.14$239.57
INV-202608-71108/01/2026R1108Seroquel 50 mg TAB9999900430131Facility$479.14$239.57
INV-202608-97508/16/2026R1118Seroquel 50 mg TAB9999900430116Facility$247.30$123.65
INV-202608-113708/24/2026R1121Seroquel 50 mg TAB999990043018Facility$123.65$61.83
INV-202609-33209/01/2026R1063Seroquel 50 mg TAB9999900430130Facility$463.68$231.84
INV-202609-57509/01/2026R1108Seroquel 50 mg TAB9999900430130Facility$463.68$231.84
INV-202609-70809/01/2026R1118Seroquel 50 mg TAB9999900430130Facility$463.68$231.84
INV-202609-85909/07/2026R1125Seroquel 50 mg TAB9999900430124Facility$370.94$185.47
INV-202609-111709/22/2026R1134Seroquel 50 mg TAB999990043019Facility$139.10$69.55
S7-004

Synthroid → generic levothyroxine (estimate; clinical review required)

Severity low Confidence low
$261.35Estimate
Evidence

9 facility-paid line(s) of brand Synthroid, $562.63 total, across 5 resident(s). A generic (levothyroxine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote. Narrow therapeutic index: monitor TSH after switching.

Contract clause

Formulary / therapeutic interchange terms (if any)

Recommended action

Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-98107/25/2026R1103Synthroid 75 mcg TAB999990045017Facility$19.99$10.00
INV-202608-77608/04/2026R1109Synthroid 75 mcg TAB9999900450128Facility$79.97$39.99
INV-202608-81408/09/2026R1111Synthroid 75 mcg TAB9999900450123Facility$65.69$32.85
INV-202608-83308/09/2026R1112Synthroid 75 mcg TAB9999900450123Facility$65.69$32.85
INV-202609-59309/01/2026R1109Synthroid 75 mcg TAB9999900450130Facility$85.68$42.84
INV-202609-61009/01/2026R1111Synthroid 75 mcg TAB9999900450130Facility$85.68$42.84
INV-202609-62909/01/2026R1112Synthroid 75 mcg TAB9999900450130Facility$85.68$42.84
INV-202609-107709/19/2026R1133Synthroid 75 mcg TAB9999900450112Facility$34.27$17.14
8

Facility charges outside Part A

$2,076.59
F8-001 · R1016

Part D rejection passed to the facility: plan limits / quantity (avoidable rejection, review)

Severity medium Confidence medium
$508.18Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 09/03/2026 were billed to the facility after the resident's plan rejected the claim (reject code 76); reason on the invoice: Plan Limitations Exceeded. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.

Census evidence

Census: R1016 in house, payer Medicaid, from 03/30/2024. Last census event: admit on 03/30/2024 (payer Medicaid).

Contract clause

§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage

Recommended action

Resubmit with the correct quantity / days supply, or request a quantity-limit exception from the plan; credit the facility for the resubmitted amount.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-84209/03/2026R1016Jardiance 10 mg TAB9999900410128Facility$505.68$505.68
INV-202609-84309/03/2026R1016Dispensing Fee999990041011Facility$2.50$2.50
F8-002 · R1013

Part D rejection passed to the facility: non-formulary (avoidable rejection, review)

Severity medium Confidence medium
$406.20Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/05/2026 were billed to the facility after the resident's plan rejected the claim (reject code MR); reason on the invoice: Product Not On Formulary. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.

Census evidence

Census: R1013 in house, payer Medicaid, from 12/29/2024. Last census event: admit on 12/29/2024 (payer Medicaid).

Contract clause

§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage

Recommended action

Ask whether the plan's transition process applies (temporary supply), request a formulary exception, or ask the prescriber to switch to a formulary alternative; resubmit and credit the facility.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-78708/05/2026R1013Linzess 145 mcg CAP9999900490127Facility$403.70$403.70
INV-202608-78808/05/2026R1013Dispensing Fee999990049011Facility$2.50$2.50
F8-003 · R1018

Part D rejection passed to the facility: other rejection (avoidable rejection, review)

Severity medium Confidence medium
$351.77Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 09/09/2026 were billed to the facility after the resident's plan rejected the claim (reject code 65); reason on the invoice: M/I Eligibility - Patient Not Covered. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.

Census evidence

Census: R1018 in house, payer Medicaid, from 11/27/2025. Last census event: admit on 11/27/2025 (payer Medicaid).

Contract clause

§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage

Recommended action

Ask the pharmacy for the full reject message, correct the eligibility or claim data, resubmit to the plan, and credit the facility.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-92309/09/2026R1018Januvia 100 mg TAB9999900470122Facility$349.27$349.27
INV-202609-92409/09/2026R1018Dispensing Fee999990047011Facility$2.50$2.50
F8-004 · R1012

Part D rejection passed to the facility: prior authorization required (avoidable rejection, review)

Severity medium Confidence medium
$298.85Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 07/14/2026 were billed to the facility after the resident's plan rejected the claim (reject code 75); reason on the invoice: Prior Authorization Required. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.

Census evidence

Census: R1012 in house, payer Medicaid, from 06/29/2024. Last census event: admit on 06/29/2024 (payer Medicaid).

Contract clause

§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage

Recommended action

Ask the prescriber and the pharmacy to request prior authorization (or a coverage determination) and a transition supply from the plan, resubmit the claim once approved, and credit the facility.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-87307/14/2026R1012Eliquis 5 mg TAB9999900400136Facility$296.35$296.35
INV-202607-87407/14/2026R1012Dispensing Fee999990040011Facility$2.50$2.50
F8-005 · R1015

Part D rejection passed to the facility: refill too soon (avoidable rejection, review)

Severity medium Confidence medium
$231.82Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/18/2026 were billed to the facility after the resident's plan rejected the claim (reject code 79); reason on the invoice: Refill Too Soon. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.

Census evidence

Census: R1015 in house, payer Medicaid, from 08/29/2024. Last census event: admit on 08/29/2024 (payer Medicaid).

Contract clause

§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage

Recommended action

Resubmit when the fill becomes payable, or request the plan's override for a dose change, LOA or lost/destroyed medication; ask the pharmacy why a facility-paid fill was dispensed early.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-101708/18/2026R1015Xarelto 20 mg TAB9999900460114Facility$229.32$229.32
INV-202608-101808/18/2026R1015Dispensing Fee999990046011Facility$2.50$2.50
F8-006 · R1135

Retroactive Medicaid eligibility: credit due for charges fronted while pending

Severity high Confidence high
$220.28Disputable
Evidence

12 drug line(s) (plus 12 linked dispensing fee(s)) dispensed 07/06/2026–09/01/2026 were billed to the facility while Medicaid eligibility was pending. The census shows Medicaid approved on 09/10/2026, effective retroactively from 07/06/2026, so these dates are now a third party's responsibility. No matching credit appears on the invoices reviewed.

Census evidence

Census: R1135 in house, payer MedicaidPending, 07/06/2026–09/09/2026. Last census event: admit on 07/06/2026 (payer MedicaidPending). Retroactive approval: Medicaid from 07/06/2026, approved 09/10/2026.

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Send the pharmacy the eligibility approval and ask it to rebill Medicaid (or the resident's Part D plan) for these dates and credit the facility. Retro claims have filing deadlines: ask now.

Dispute deadline

10/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202607-71107/06/2026R1135Atorvastatin 40 mg TAB9999900020126Facility$24.57$24.57
INV-202607-71207/06/2026R1135Docusate 100 mg CAP9999900140152Facility$1.87$1.87
INV-202607-71307/06/2026R1135Escitalopram 10 mg TAB9999900230126Facility$17.55$17.55
INV-202607-71407/06/2026R1135Mirtazapine 15 mg TAB9999900240126Facility$12.87$12.87
INV-202608-72008/01/2026R1135Atorvastatin 40 mg TAB9999900020131Facility$29.30$29.30
INV-202608-72108/01/2026R1135Docusate 100 mg CAP9999900140162Facility$2.23$2.23
INV-202608-72208/01/2026R1135Escitalopram 10 mg TAB9999900230131Facility$20.93$20.93
INV-202608-72308/01/2026R1135Mirtazapine 15 mg TAB9999900240131Facility$15.35$15.35
INV-202609-78209/01/2026R1135Atorvastatin 40 mg TAB9999900020130Facility$28.35$28.35
INV-202609-78309/01/2026R1135Docusate 100 mg CAP9999900140160Facility$2.16$2.16
INV-202609-78409/01/2026R1135Escitalopram 10 mg TAB9999900230130Facility$20.25$20.25
INV-202609-78509/01/2026R1135Mirtazapine 15 mg TAB9999900240130Facility$14.85$14.85
INV-202607-71507/06/2026R1135Dispensing Fee999990002011Facility$2.50$2.50
INV-202607-71607/06/2026R1135Dispensing Fee999990014011Facility$2.50$2.50
INV-202607-71707/06/2026R1135Dispensing Fee999990023011Facility$2.50$2.50
INV-202607-71807/06/2026R1135Dispensing Fee999990024011Facility$2.50$2.50
INV-202608-72408/01/2026R1135Dispensing Fee999990002011Facility$2.50$2.50
INV-202608-72508/01/2026R1135Dispensing Fee999990014011Facility$2.50$2.50
INV-202608-72608/01/2026R1135Dispensing Fee999990023011Facility$2.50$2.50
INV-202608-72708/01/2026R1135Dispensing Fee999990024011Facility$2.50$2.50
INV-202609-78609/01/2026R1135Dispensing Fee999990002011Facility$2.50$2.50
INV-202609-78709/01/2026R1135Dispensing Fee999990014011Facility$2.50$2.50
INV-202609-78809/01/2026R1135Dispensing Fee999990023011Facility$2.50$2.50
INV-202609-78909/01/2026R1135Dispensing Fee999990024011Facility$2.50$2.50
F8-007 · R1019

Possible hospice responsibility: drugs billed to the facility during hospice care

Severity medium Confidence medium
$30.83Disputable
Evidence

2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/19/2026 were billed to the facility while the resident was under hospice care (hospice election 08/18/2026). Under 42 CFR 418.106, drugs related to the palliation and management of the terminal illness and related conditions, as identified in the hospice plan of care, must be provided by the hospice while the patient is under hospice care. The invoice carries no diagnosis, so relatedness is not confirmed. Drugs unrelated to the terminal prognosis are normally billed to Part D or Medicaid, not the facility, so the facility should not be the payer either way.

Census evidence

Census: R1019 in house, payer Medicaid, from 04/23/2026. Last census event: admit on 04/23/2026 (payer Medicaid). Hospice: hospice election 08/18/2026.

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Confirm relatedness with the hospice and the consultant pharmacist against the hospice plan of care. For related drugs, bill the hospice (see the draft request to the hospice) or ask the pharmacy to bill the hospice and credit the facility. For unrelated drugs, ask the pharmacy to rebill Part D / Medicaid.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-101908/19/2026R1019Morphine Sulfate 20 mg/mL ORAL SOLN9999900650128Facility$20.16$20.16
INV-202608-102008/19/2026R1019Haloperidol 0.5 mg TAB9999900660128Facility$5.67$5.67
INV-202608-102108/19/2026R1019Dispensing Fee999990065011Facility$2.50$2.50
INV-202608-102208/19/2026R1019Dispensing Fee999990066011Facility$2.50$2.50
F8-008 · R1001

Possible hospice responsibility: drugs billed to the facility during hospice care

Severity medium Confidence medium
$22.66Disputable
Evidence

1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/10/2026 were billed to the facility while the resident was under hospice care (census payer Hospice). Under 42 CFR 418.106, drugs related to the palliation and management of the terminal illness and related conditions, as identified in the hospice plan of care, must be provided by the hospice while the patient is under hospice care. The invoice carries no diagnosis, so relatedness is not confirmed. Drugs unrelated to the terminal prognosis are normally billed to Part D or Medicaid, not the facility, so the facility should not be the payer either way.

Census evidence

Census: R1001 in house, payer Hospice, from 11/06/2024. Last census event: admit on 11/06/2024 (payer Hospice). Hospice: census payer Hospice.

Contract clause

§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party

Recommended action

Confirm relatedness with the hospice and the consultant pharmacist against the hospice plan of care. For related drugs, bill the hospice (see the draft request to the hospice) or ask the pharmacy to bill the hospice and credit the facility. For unrelated drugs, ask the pharmacy to rebill Part D / Medicaid.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-84408/10/2026R1001Morphine Sulfate 20 mg/mL ORAL SOLN9999900650128Facility$20.16$20.16
INV-202608-84508/10/2026R1001Dispensing Fee999990065011Facility$2.50$2.50
F8-009 · R1022

OTC priced above contract: Bisacodyl 5 mg TAB EC (OTC)

Severity medium Confidence high
$3.60Disputable
Evidence

2 facility-paid OTC / house-stock line(s) of Bisacodyl 5 mg TAB EC (OTC) dispensed 08/01/2026–09/01/2026 on days outside a facility-responsible stay, billed at $0.12 per unit. Contract ceiling: OTC price list (NDC 99999007001) = $0.0600 per unit. OTC drugs are generally not covered by Part D, so the facility is often the payer; the price still has to match the agreement.

Census evidence

Census: R1022 in house, payer Medicaid, from 03/14/2026. Last census event: admit on 03/14/2026 (payer Medicaid).

Contract clause

Exhibit B §3 (House Stock and OTC): OTC items at the Exhibit B-3 price list

Recommended action

Request credit for the difference and ask the pharmacy to correct its OTC price file.

Dispute deadline

11/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202608-12908/01/2026R1022Bisacodyl 5 mg TAB EC (OTC)9999900700130Facility$3.60$1.80
INV-202609-11509/01/2026R1022Bisacodyl 5 mg TAB EC (OTC)9999900700130Facility$3.60$1.80
F8-010 · R1025

OTC priced above contract: Calcium Carbonate 500 mg CHEW TAB (OTC)

Severity medium Confidence high
$2.40Disputable
Evidence

1 facility-paid OTC / house-stock line(s) of Calcium Carbonate 500 mg CHEW TAB (OTC) dispensed 09/01/2026 on days outside a facility-responsible stay, billed at $0.11 per unit. Contract ceiling: OTC price list (NDC 99999007201) = $0.0700 per unit. OTC drugs are generally not covered by Part D, so the facility is often the payer; the price still has to match the agreement.

Census evidence

Census: R1025 in house, payer Medicaid, from 08/08/2024. Last census event: admit on 08/08/2024 (payer Medicaid).

Contract clause

Exhibit B §3 (House Stock and OTC): OTC items at the Exhibit B-3 price list

Recommended action

Request credit for the difference and ask the pharmacy to correct its OTC price file.

Dispute deadline

12/29/2026

LineServiceResidentItemNDC QtyBilled toLine totalFlagged
INV-202609-12809/01/2026R1025Calcium Carbonate 500 mg CHEW TAB (OTC)9999900720160Facility$6.60$2.40
Monitoring and data quality

What to watch, and what we received.

Credits to confirm next month and pending credits to watch

Files received

FileNameRows readLoaded RejectedUnmapped columns
invoicesinvoices.csv3,4333,4330—
censuscensus.csv2682680—
Methodology and limitations

How we tested, and what this is not.

Method

  1. Census timeline. Each resident's census events were turned into a day-by-day record of payer and status. Arrivals count from the event date. Discharge, death, leave of absence and hospital transfer count from the next day, so medication sent with a resident on the day they leave is not flagged.
  2. Payer. Each drug line's service date was matched to the payer that day and to the agreement's billing-responsibility terms. Basis: dispense date.
  3. Departures. Facility-billed lines dated on days the resident was not in the building.
  4. Duplicates and credits. Repeat charges; early refills with no credit; unused, returnable supply at discharge or death without a credit within 30 days (controlled substances excluded; minimum 3 unused days).
  5. Fees. Every fee line against the agreement's fee schedule, frequency caps and the list of permitted fees.
  6. Consolidated billing. Facility-billed drugs on Part A days that match the SNF consolidated billing exclusion categories (chemotherapy, ESRD-related drugs).
  7. Price. Unit price against the contract formula (brand AWP less 16%, generic AWP less 55%), using the AWP printed on the invoice.
  8. Substitution. Facility-paid brand drugs with established generics. Estimate only.
  9. Outside Part A. Every facility-billed drug line on a day outside a facility-responsible stay, classified as hospice, Medicaid pending (retroactive approval), OTC (against contract OTC terms), Part D rejection passed through, legitimate under the agreement, or should have gone to Part D / Medicaid (check 1).

Limitations

  • Findings are only as complete as the files received. Lines billed to third parties are visible only if the pharmacy's billing detail includes them.
  • Price testing uses the AWP printed on the pharmacy's invoice, not an independent licensed AWP source.
  • The consolidated-billing and substitution lists are bundled reference subsets. Every match must be verified against the current CMS exclusion file and by the clinical pharmacist.
  • Missing-credit findings assume the medication was returnable and returned. Confirm with the facility's return or destruction log.
  • Early-refill findings can be explained by dose changes; they carry low confidence.
  • Hospice findings are possible responsibility only: without diagnoses we cannot confirm a drug is related to the terminal prognosis. Part D rejection findings need human review of whether the rejection was avoidable. OTC detection without an OTC column uses a short bundled name list.
  • The annualized figure is an estimate (period findings × 365 / period days), not a result.
  • This report is not legal advice. The facility decides what to dispute and how to address compliance findings.
Review and sign-off

Software-backed review, signed off by a clinical pharmacist.

Clinical pharmacist review

I reviewed the consolidated-billing, substitution and clinically dependent findings in this report.

Name, RPh / PharmD · License no. · State
Signature · Date
Audit analyst review

I reviewed every finding against the source invoice lines, census and agreement.

Name · Title
Signature · Date